Vaccination greatly reduces disease, disability, death and inequity worldwide

Bulletin of the World Health Organization

Volumn 86, Issue 2, 2008, Pages 140-146

  Andre, F E ^a   Booy, R ^b   Bock, H L ^c   Clemens, J ^d   Datta, S K ^c   John, T J ^e   Lee, B W ^f   Lolekha, S ^g   Peltola, H ^h   Ruff, T A ⁱ   Santosham, M ^j   Schmitt, H J ^k  

^a Children's Hospital Westmead ^*  (Belgium)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d International Vaccine Institute   (South Korea)

^e CHRISTIAN MEDICAL COLLEGE   (India)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g MAHIDOL UNIVERSITY   (Thailand)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k JOHANNES GUTENBERG UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; TYPHOID VACCINE; WART VIRUS VACCINE;

ANTIBIOTIC RESISTANCE; CANCER; CARDIOVASCULAR DISEASE; DEVELOPING WORLD; DISABILITY; DISEASE INCIDENCE; ECONOMIC GROWTH; HEALTH CARE; HEALTH EXPENDITURE; IMMUNIZATION; INCOME DISTRIBUTION; INFLUENZA; MORBIDITY; MORTALITY;

ANTIBIOTIC RESISTANCE; BIOLOGICAL WARFARE; DEATH; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; HEALTH CARE; HEALTH CARE COST; HEALTH SERVICE; HEPATITIS A; HUMAN; IMMUNIZATION; LIFE EXPECTANCY; MORBIDITY; MORTALITY; MUMPS; NONHUMAN; POLIOMYELITIS; REVIEW; RUBELLA; VACCINATION; VIRUS INFECTION;

ACUTE DISEASE; CHRONIC DISEASE; DISABLED PERSONS; HEALTH POLICY; HEALTH PROMOTION; HEALTH STATUS DISPARITIES; HUMANS; IMMUNIZATION PROGRAMS; MORTALITY; POVERTY; PREVENTIVE HEALTH SERVICES; PUBLIC HEALTH; SOCIOECONOMIC FACTORS; VACCINATION; WORLD HEALTH;

EID: 38949165668     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.07.040089     Document Type: Review

References (69)

1. Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th edn. Philadelphia: WB Saunders; 2004: 1-15.
2. Global Advisory Committee on Vaccine Safety. 3-4 December 2003. Wkly Epidemiol Rec 2004;79:16-20.
3. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunisation: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003; 52:1-24.
4. MacIntyre CR, Leask J. Immunisation myths and realities: responding to arguments against immunisation. J Paediatr Child Health 2003;39:487-91. doi:10.1046/j.1440-1754.2003.t01-1-00200.x
5. Folb PI, Bernastowska E, Chen R, Clemens J, Dodoo AN, Ellenberg SS, et al. A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety. Am J Public Health 2004;94:1926-31.
6. Atkinson P, Cullinan C, Jones J, Fraser G, Maguire H. Large outbreak of measles in London: reversal of health inequalities. Arch Dis Child 2005;90:424-5. doi:10.1136/adc.2003.048892
7. Medline website. Available from: http://www.pubmed.gov
8. Andre FE. What can be done to make vaccines more trendy? Expert Rev Vaccines 2005;4:23-5. doi:10.1586/14760584.4.1.23
9. Henderson DA. Lessons from the eradication campaigns. Vaccine 1999; 17:S53-5. doi:10.1016/S0264-410X(99)00293-5
10. Fine PE, Griffiths UK. Global poliomyelitis eradication: status and implications. Lancet 2007;369:1321-2. doi:10.1016/S0140-6736(07)60533-9
11. Muller CP, Kremer JR, Best JM, Dourado I, Triki H, Reef S. WHO Steering Committee for Measles and Rubella. Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 2007;25:1-9. doi:10.1016/j.vaccine.2006.07.039
12. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA 2000;284:2643-7. doi:10.1001/jama.284.20.2643
13. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006;81:445-52.
14. Polio reported in Botswana. Geneva: WHO; 2004. Available from: http://www.who.int/mediacentre/notes/2004/np11/en
15. Parker AA, Staggs W, Dayan GH, Ortega-Sanchez IR, Rota PA, Lowe L, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006;355:447-55. doi:10.1056/NEJMoa060775
16. Schmitt HJ, von Kries R, Hassenpflug B, Hermann M, Siedler A, Niessing W, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids - acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001;20:767-74.
17. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003;21:2015-21. doi:10.1016/S0264-410X(02) 00777-6
18. Succi RC, Farhat CK. Vaccination in special situations. J Pediatr (Rio J) 2006; 82:S91-100. doi:10.2223/JPED.1474
19. Ehreth J. The global value of vaccination. Vaccine 2003;21:596-600. doi:10.1016/S0264-410X(02)00623-0
20. Anon. Impact of vaccines universally recommended for children. 1900-1998. Mortal Morb Wkly Rep 1999;48:243-8.
21. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okobo JB, et al. Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-46. doi:10.1016/S0140-6736(05)71876-6
22. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. doi:10.1056/NEJMoa052434
23. Schmitt HJ, von Konig CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41. doi:10.1001/jama.275.1.37
24. Preziosi M-P, Halloran ME. Effect of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003;37:772-9. doi:10.1086/377270
25. Vazquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851-5. doi:10.1001/jama.291.7.851
26. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakol W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328-34. doi:10.1001/jama.271.17.1328
27. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55. doi:10.1016/S0140-6736(06)68439-0
28. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19:877-85. doi:10.1016/S0264-410X(00)00224-3
29. Adegbola R, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of Haemophilus influenzae type b (Hib) disease from the Gambia after introduction of a Hib conjugate vaccine: a prospective study. Lancet 2005;366:144-50. doi:10.1016/S0140-6736(05)66788-8
30. Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000;29:753-6. doi:10.1093/ije/29.4.753
31. Schlenker TL, Bain C, Baughman AL, Hadler SC. Measles herd immunity: the association of attack rates with immunization rates in preschool children. JAMA 1992;267:823-6. doi:10.1001/jama.267.6.823
32. Ali M, Emch M, von Seidlein L, Yunus M, Sack D, Rao M, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh. Lancet 2005; 366:44-9. doi:10.1016/S0140-6736(05)66550-6
33. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000;16:601-6. doi:10.1023/A:1007626510002
34. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1991.
35. Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 2004;181:482-5.
36. Andre FE. Universal mass vaccination against hepatitis A. In: Plotkin SA, ed. Mass vaccination: global aspects - progress and obstacles. Current Topics in Microbiology 2006; 304: 95-114.
37. Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004;38:705-15. doi:10.1086/381671
38. Crowcroft NS, Booy R, Harrison T, Spicer L, Britto J, Mok Q, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 2003;88:802-6. doi:10.1136/adc.88.9.802
39. Manzoli L, Schioppa F, Boccia A, Villari P. The efficacy of the influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 2007; 26:97-106. doi:10.1097/01.inf.0000253053.01151.bd
40. Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th ed. Philadelphia: WB Saunders; 2004; 389-440.
41. Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P, et al. Prevention of travellers' diarrhoea by oral B - subunit/whole-cell cholera vaccine. Lancet 1991;338:1285-9. doi:10.1016/0140-6736(91)92590-X
42. Chang MH. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003;23:309-24. doi:10.1034/j.1478-3231.2003.00865.x
43. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004;39:211-9. doi:10.1002/hep.20027
44. Aristegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, et al. Facilitating the WHO Expanded Programme of Immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis 2003;7:143-51. doi:10.1016/S1201-9712(03)90011-7
45. Decker MD. Principles of paediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Inf Dis J 2001;20:S10-8. doi:10.1097/00006454-200111001-00002
46. Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, et al. Cost effectiveness of a routine varicella program for US children. JAMA 1994; 271:375-81. doi:10.1001/jama.271.5.375
47. Bloom DE, Canning D, Weson M. The value of vaccination. World Econ 2005; 6:15-39.
48. Chabot I, Goetghebeur MM, Gregoire J-P. The societal value of universal childhood vaccination. Vaccine 2004;22:1992-2005. doi:10.1016/j.vaccine. 2003.10.027
49. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B, Streptococcus pneumoniae conjugate and rotavirus vaccines in immunization schedules. Health Econ 2000;9:19-35. doi:10.1002/(SICI)1099-1050(200001)9:1〈19::AID-HEC487〉3.0.CO;2-C
50. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63. doi:10.1056/NEJMoa051642
51. Parry CM. Typhoid fever. Curr Infect Dis Rep 2004;6:27-33. doi:10.1007/s11908-004-0021-6
52. Lieberman JM. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. Pediatr Infect Dis J 2003;22:1143-51. doi:10.1097/01.inf.0000101851.57263.63
53. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccinations and reductions in hospitalisations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322-32. doi:10.1056/ NEJMoa025028
54. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004;23:363-8. doi:10.1183/09031936.04.00063504
55. Klaber R, Booy R, El Bashir H, Mifsud A, Taylor S. Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet 2002;360:644. doi:10.1016/S0140-6736(02)09795-7
56. Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet 2006; 367:1008-15. doi:10.1016/S0140-6736(06)68429-8
57. Steffen R, Banos A, de Bernardis C. Vaccination priorities. Int J Antimicrob Agents 2003;21:175-80. doi:10.1016/S0924-8579(02)00286-8
58. Nothdurft HD, Zuckerman J, Stoffel M, Dieussaert I, van Damme P. Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travelers. J Travel Med 2004;11:260-1.
59. Shearley AE. The societal value of vaccination in developing countries. Vaccine 1999;17:S109-12. doi:10.1016/S0264-410X(99)00303-5
60. Ruff TA, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, et al. Lombok Hepatitis B Model Immunisation Project: Toward universal infant hepatitis B immunisation in Indonesia. J Infect Dis 1995;171:290-6.
61. Martines J, Paul VK, Bhutta ZA, Koblinsky M, Soucat A, Walker N, et al. Lancet Neonatal Survival Steering Team. Neonatal survival: a call for action. Lancet 2005;365:1189-97. doi:10.1016/S0140-6736(05)71882-1
62. Hassani M, Patel MC, Pirofski LA. Vaccines for the prevention of diseases caused by potential bioweapons. Clin Immunol 2004;111:1-15. doi:10.1016/j.clim.2003.09.010
63. Press release, 8 July 2004. Pan American Health Organization. Available from: http://www.paho.org/English/DD/PIN/pr040708.htm
64. Wagstaff A. Poverty and health sector inequalities. Bull World Health Organ 2002;80:97-105.
65. Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004;291:2197-203. doi:10.1001/jama.291.18.2197
66. Bishai D, Koenig M, Ali Khan M. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ 2003;12:415-9. doi:10.1002/hec.732
67. Hotez PJ. Vaccines as instruments of foreign policy. EMBO Rep 2001;2:862-8. doi:10.1093/embo-reports/kve215
68. Immunization profile - Sri Lanka. Geneva: WHO. Available from: http://www.who.int/vaccines/globalsummary/immunization/countryprofileresult.cfm? C=
69. Stalenheim P, Fruchart D, Omitoogun W, Perdomo C. Military expenditure. In: Stockholm International Peace Research Institute (SIPRI). SIPRI Yearbook 2006. Oxford: Oxford University Press; 2006: 295-386.